Typhoid Fever Clinical Trial
Official title:
Vellore Typhoid Vaccine Impact Trial
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
TyphiBEV®, a typhoid conjugate vaccine from Biological E, has been licensed by the Central Drugs Standard Control Organaisation in India based on immunogenicity and safety data. A similar typhoid conjugate vaccine has been demonstrated in large clinical trials to provide 80% vaccine efficacy in Nepal and Bangladesh. The TyphiBEV® has not been similarly evaluated. The demonstration of the impact of a city-scale typhoid conjugate vaccine introduction on the burden of typhoid will aid policy decisions on the use of typhoid conjugate vaccines in the national immunisation program. After written informed consent, the investigators will establish stimulated passive surveillance in 72,000 individuals between 1 and 30 years of age within the Vellore Demographic Surveillance System to determine the incidence of blood-culture confirmed typhoid fever. Thirty-six thousand surveillance participants between 1 year and 30 years residing in the 30 clusters (areas) randomised to receive the vaccine will receive the vaccine at the beginning of the trial. Those in other areas will receive the same at the end of two years. Using a stimulated passive surveillance approach, those with acute febrile illness will be encouraged to visit study surveillance hospitals. Participants will be evaluated for blood-culture confirmed typhoid fever if they are eligible. The incidence of typhoid among those living in areas assigned to vaccination compared to those whose residence is in areas not designated for vaccination will be used to calculate the impact of the vaccine on disease burden. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04830371 -
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
| Completed |
NCT02324751 -
Vaccines Against Salmonella Typhi
|
Phase 2 | |
| Completed |
NCT01421693 -
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
|
Phase 4 | |
| Completed |
NCT05579821 -
Evaluation Study of DPP® Typhoid Assay
|
||
| Completed |
NCT02947295 -
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
|
||
| Completed |
NCT01405521 -
Understanding Typhoid Disease After Vaccination
|
Phase 2 | |
| Completed |
NCT00386789 -
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
|
N/A | |
| Completed |
NCT04801602 -
Commercial Typhoid Tests Validation Trial
|
||
| Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
| Completed |
NCT01438996 -
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
|
Phase 2 | |
| Completed |
NCT01437267 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
|
Phase 2 | |
| Completed |
NCT01193907 -
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
|
Phase 2 | |
| Recruiting |
NCT04349826 -
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
|
Phase 4 | |
| Completed |
NCT01608815 -
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
|
Phase 3 | |
| Completed |
NCT01123941 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
|
Phase 1 | |
| Completed |
NCT03926455 -
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
|
Phase 1 | |
| Completed |
NCT01229176 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
|
Phase 2 | |
| Completed |
NCT03956524 -
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT04154722 -
Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
|
Phase 4 |